EITR BIOLOGICS, INC.

San Diego, CA · Biotech · Private

Half-life extended monoclonal antibodies (mAbs) against coronavirus spike proteins, specifically AR-703 for SARS-CoV-2 and MERS

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · eitrbio.com

Sector: Biotech
Headquarters: San Diego, CA
Total capital: $41.5M

Federal grants: $1.9M; 4 awards · 2023–2025; Rank in peer group#355 of 514
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: $39.6M; 10 awards · Defense, Health and Human S; Rank in Biotech#20 of 4373
Granted patents: 0; 2 pending

Capital timeline

Latest events

Jul 2026Federal contractDefense · Novel Bispecific Broad Spectrum Nanobody$100K
Apr 2026Federal contractDefense · Novel Bispecific Broad Spectrum Nanobody$270K
Feb 2026Federal contractDefense · Novel Bispecific Broad Spectrum Nanobody$927K
Sep 2025Federal grantHealth and Human S · Phase II · Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure$1M
Jul 2025Federal contractDefense · Novel Nanotherapeutics$300K
Sep 2024Federal contractDefense · Novel Nanotherapeutics$1.9M
Jul 2024Federal contractDefense · Develop A Novel Odin Therapeutic Medical Countermeasure Capable Of Protecting Against Pneumonic Unencapsulated Y. Pestis.$500K

Show 7 earlier federal awards

Dec 2023Federal contractDefense · Sorting Peripheral Blood Mononuclear Cells From Lassa Fever Virus Survivors To Discover And Produce Monoclonal Antibodies For Assessment In In Vitro And In Vivo Assays$730K
Sep 2023Federal grantHealth and Human S · Phase I · Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape$300K
Sep 2023Federal contractHealth and Human S · The Development Of A Multimodal Antibody Platform To Extend The Window Of Immunotherapeutic Intervention. The Overall Objective Of The Work Outlined In This Contract Is To Critically Evaluate The Utility Of The Vhh As A Platform Mcm Technology For Vi$33.1M
Sep 2023Federal contractDefense · Novel Nanotherapeutic Approaches Penetrating The Outer Layers Of The Bacterium And Targeting Outer Membrane Proteins For The Treatment Of Pneumonic Plague For Assessment In In Vitro And In Vivo Assays$750K
Aug 2023Federal grantHealth and Human S · Phase I · PA-22-176, SBIR, Phase I, Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape$300K
Jul 2023Federal grantHealth and Human S · Phase I · Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure$284K
Nov 2022Federal contractDefense · Novel Cell Sorting$1.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 514 peers

Line = median

Biotech · Molecule

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

USPTO · 0 granted of 2

Jul 17, 2025PendingPlatform Technology For Bispecific Antigenbinding ProteinsUSPTOApplication 18980683
PendingPlatform Technology For Bispecific Antigen-binding ProteinsUSPTOApplication 63353989

Invirsa, Inc.Similar federal contract value in Biotech · $48M in contracts
OPHIREX, INCSimilar federal contract value in Biotech · $46.2M in contracts
METABOLON, INC.Similar federal contract value in Biotech · $42M in contracts
Sciome LLCSimilar federal contract value in Biotech · $39.3M in contracts
Soligenix, IncSimilar federal contract value in Biotech · $39.1M in contracts
PROFECTUS BIOSCIENCES, INC.Similar federal contract value in Biotech · $38.3M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.